



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

[http ://www.uniquepharma.com](http://www.uniquepharma.com)

StockExchange-NSE letters/MM:SA:315

July 29, 2011

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai 400 051.

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Unaudited Financial Results for the quarter ended on June 30, 2011.

Enclosed please find unaudited financial results for the quarter ended on June 30, 2011. These financial results have been approved and taken on record by the board of directors at its meeting held today.

We request you to take the above on record.

Thanking you,

Yours faithfully,
for J. B. Chemicals & Pharmaceuticals Limited


M. C. Mehta
Company Secretary - General Manager



J. B. Chemicals & Pharmaceuticals Limited

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2011

Sr. No.	PARTICULARS	Rs. in Lakhs		
		QUARTER ENDED		YEAR ENDED
		30/06/2011	30/06/2010	31/03/2011 (Audited)
1	a) Net Sales (Net of excise)	17,744.41	15,886.97	78,757.94
	b) Other Operating Income	512.10	434.39	1,912.61
	Total Income	18,256.51	16,321.36	80,670.55
2	Expenditure			
	a) (Increase)/Decrease in Stock in Trade & WIP	242.27	366.59	(1,286.13)
	b) Consumption of Raw Materials	5,109.91	4,180.34	20,900.33
	c) Purchase of Traded Goods	1,388.67	1,342.47	4,691.52
	d) Employees Cost	3,110.30	2,482.05	11,642.70
	e) Depreciation	567.50	547.50	2,265.08
	f) Sales Promotion & Publicity	1,254.04	1,131.56	10,527.89
	g) Exchange Fluctuation Suffered (Gain)/Loss	(5.32)	(4.93)	16.75
	h) Other Expenditure	3,868.78	3,362.18	17,234.34
	Total	15,536.15	13,407.76	65,992.48
3	Profit from operations before Other Income & Interest (1-2)	2,720.36	2,913.60	14,678.07
4	Other Income	418.33	93.40	586.79
5	Profit before Interest (3+4)	3,138.69	3,007.00	15,264.86
6	Interest	180.66	183.68	737.30
7	Profit after Interest but before Exchange Fluctuation Gain / (Loss) (5-6)	2,958.03	2,823.32	14,527.56
8	Exchange Fluctuation Gain / (Loss)	(269.80)	(355.43)	(422.22)
9	Profit from Ordinary Activities Before Tax (7-8)	2,688.23	2,467.89	14,105.34
10	Tax Expenses :			
	Current Tax	753.00	495.00	2,810.00
	MAT Credit Entitlement	-	(80.00)	(550.00)
	Deferred Tax	30.31	(14.20)	19.63
	Short/(Excess) Provision for Taxation for prior year	-	(2.34)	6.25
11	Profit from Ordinary Activities After Tax (9-10)	1,904.92	2,069.43	11,819.46
12	Paid-up Equity Share Capital (Face Value Rs. 2/- per share)	1,692.53	1,687.38	1,690.34
13	Reserves (excluding Revaluation Reserve) as per balance sheet of previous accounting year	-	-	69,637.93
14	Earnings Per Share (EPS)			
	a) Basic (Not annualised)	2.25	2.45	14.00
	b) Diluted (Not annualised)	2.25	2.45	13.96
15	Public Shareholding			
	No. of shares	37,762,235	37,511,035	37,663,735
	% of shareholding	44.62	44.46	44.56
16	Promoters and Promoter Group Shareholding			
	a) Pledged/Encumbered			
	Number of shares	5,000	-	-
	Percentage of shares (as a % of the shareholding of promoter and promoter group)	0.01	-	-
	Percentage of shares (as a % of the total share capital of the company)	0.01	-	-
	b) Non-encumbered			
	Number of shares	46,859,090	46,858,090	46,853,090
	Percentage of shares (as a % of the shareholding of promoter and promoter group)	99.99	100	100
	Percentage of shares (as a % of the total share capital of the company)	55.37	55.54	55.44

NOTES :

1. The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on July 29, 2011.
2. On July 14, 2011, the company has closed the transaction of sale of its Russia-CIS OTC products business to Cilag GmbH International, a wholly owned subsidiary of Johnson & Johnson.
3. The board of directors, at its meeting held on July 22, 2011, has approved entering into definitive agreement for sale of the company's Russia-CIS prescription products business to Dr. Reddy's Laboratories Ltd. for consideration of about Rs.137/- crores.
4. There were no outstanding complaints from investors at the beginning of the quarter. The company received 2 complaints from the investors during the quarter, which have been disposed of during the quarter.
5. The company is engaged in a single segment of activity namely, "Pharmaceuticals".
6. During the quarter, the company allotted 1,09,500 equity shares against exercise of stock options.
7. Previous quarter's / period's figures have been regrouped / re-stated, wherever necessary.

For J.B. CHEMICALS & PHARMACEUTICALS LTD.



Place : Mumbai
Date : July 29, 2011

J.B.MODY
CHAIRMAN & MANAGING DIRECTOR